Zaire ebolavirus
| Nitazoxanide | EBOV | Pyruvate inhibitor | Phase 2 | — | Human pyruvate synthase | |
| Remdesivir | EBOV | Viral RNA polymerase inhibitor | Approved (other) | Japan | Viral RNA pol | |
| ABMA | EBOV | Prevents endosomal fusion/maturation | Preclinical | — | Human GTPase | |
| Amiloride | EBOV | Epithelial sodium channel inhibitor | Preclinical | — | Human ion channel | |
| Amiodarone | EBOV | Non-competitive β-adrenergic inhibitor | Phase 3 | — | Human (multiple) | |
| Amodiaquine | EBOV | Methyltransferase inhibitor | Preclinical | — | Human HNMT | |
| Apilimod | EBOV | PIKfyve kinase inhibitor | Preclinical | — | Human PTK | |
| Artesunate | EBOV | Unclear | Phase 3 | — | Unknown | |
| Azithromycin | EBOV | — | Phase 2 | — | Human (multiple) | |
| Benztropine | EBOV | Selective inhibition of dopamine transporters but it also presents affinity for histamine and muscarine receptors | Preclinical | — | Human CHRM1 | |
| Bepridil | EBOV | Calcium / Potassium / Sodium channel antagonist | Preclinical | — | Human ion channel | |
| Brincidofovir | EBOV | Viral DNA polymerase inhibitor | Phase 2 | — | Viral RNA pol | |
| Chloroquine | EBOV | Antimalaria agent; chemo/radio sensitizer | Preclinical | — | Human (multiple) | |
| Chlorpromazine | EBOV | Inhibits assembly of clathrin-coated pits at the plasma membrane | Preclinical | — | Human (multiple) | |
| Clomipramine | EBOV | — | Preclinical | — | Human (multiple) | |
| DABMA | EBOV | Prevents endosomal fusion/maturation | Preclinical | — | Human GTPase | |
| Dalbavancin | EBOV | — | Preclinical | — | Unknown | |
| Diphenhydramine | EBOV | Prevent viral entry | Preclinical | — | Human histamine receptor | |
| Dyphillin | EBOV | vacuolar ATPase inhibitors | Preclinical | — | Human vATPase | |
| Emetine | EBOV | — | Preclinical | — | Human ribosome | |
| Erlotinib | EBOV | EGFR inhibitor | Phase 2 | — | Human PTK | |
| Esomeprazole | EBOV | Proton pump inhibitor | Preclinical | — | Human vATPase | |
| Favipiravir | EBOV | Viral RNA polymerase inhibitor | Approved (other) | Japan | Viral RNA pol | |
| Fluphenazine | EBOV | Prevent viral entry | Preclinical | — | Human ion channel | |
| Galidesivir | EBOV | RNA-dependent RNA polymerase (RdRp) inhibitor | Preclinical | — | Viral RNA pol |